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Abstract: Allogeneic hematopoietic transplantation (allo-HCT) is a curative therapy for a
variety of hematologic malignancies, primarily through immune-mediated clearance of
malignant cells. This graft-versus-leukemia (GvL) effect is mediated by alloreactive donor
T-cells against recipient malignant cells. Unfortunately, graft versus host disease is a
potentially lethal complication of this procedure, also mediated by alloreactive donor T-cells
against recipient normal tissues. Graft-versus-host disease (GVHD) remains a key contributor
to nonrelapse mortality and long-term morbidity in patients undergoing allo-HCT. Reducing
GVHD without interfering with – or ideally while enhancing – GvL, would improve outcomes
and increase patient eligibility for allo-HCT. The JAK/STAT signaling pathway acts downstream
of over 50 cytokines and is central to a wide variety of inflammatory pathways. These pathways
play a role in the development and maintenance of GVHD throughout the disease process and
within T-cells, B-cells, macrophages, neutrophils, and natural killer cells. Agents targeting
JAK/STAT signaling pathways have shown clinical efficacy and gained US Food and Drug
Administration approval for numerous diseases. Here, we review the preclinical and clinical
evidence for the role of JAK/STAT signaling in the development and maintenance of GVHD and
the utility of blocking agents at preventing and treating GVHD.
Keywords: Graft-versus-host disease, GVHD, JAK/STAT signaling
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Introduction
Allo-HCT and GVHD
Allogeneic hematopoietic cell transplantation
(allo-HCT) is a potentially curative therapy for an
array of hematological malignancies. Efficacy is
mediated, in large part, through the graft versus
leukemia (GvL) effect, and alloreactivity of donor
T-cells against host leukemic cells.1 Grafted donor
immune cells recognize leukemic cells as foreign
and eliminate them. Evidence for GvL comes from
a number of observations: patients who relapse
after allo-HCT can achieve remission after stopping immunosuppression or with donor lymphocyte infusions, allo-HCT with reduced intensity
conditioning regimens can induce remission in
acute myeloid leukemia (AML), T-cell depleted

grafts have higher rates of relapse, and patients
with AML who develop graft-versus-host disease
(GVHD), especially chronic GVHD (cGVHD),2
after allo-HCT have a lower rate of relapse.
Unfortunately, this donor cell reactivity against
malignant cells is coupled with donor cell reactivity
against normal host tissues, which leads to GVHD.
GVHD is one of the main sources of morbidity and
mortality after allo-HCT, limiting the use of this
potentially curative therapy. GVHD can be classified
as acute GVHD (aGVHD), cGVHD, and overlap
syndrome, which presents with 
features of both.
aGVHD occurs in 25–55% of patients after alloHCT, and cGVHD in 40% of patients. GVHD is
life-threatening in 15–20% of patients. A Center for
International Blood and Marrow Transplant Research
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Table 1. Cytokine receptors and downstream JAKs
and STATs.9
Cytokine

JAKs

STATs

IFNγ

JAK1/JAK2

STAT 1/STAT1

IFNα/β

JAK1/TYK2

STAT1/STAT2

IL-6

JAK1/JAK2

STAT3/STAT3

IL-12

JAK2/TYK2

STAT4/STAT4

IL-3

JAK2/JAK2

STAT5a/STAT5b

GM-CSF

JAK2/JAK2

STAT5a/STAT5b

IL-2

JAK1/JAK3

STAT5a/STAT5b

IL-4

JAK1/JAK3

STAT6/STAT6

IL-13

JAK1/JAK3

STAT6/STAT6

EPO

JAK2/JAK2

STAT3/STAT5

MPL

JAK2/JAK2

STAT3/STAT5

EPO, erythropoietin; GM-CSF, Granulocyte-macrophage
colony-stimulating factor; IFNα/β, interferon alpha/
beta; IFNγ, interferon gamma; IL, interleukin; JAK, Janus
kinases; MPL, myeloproliferative leukemia virus oncogene;
STAT, signal transducers and activation of transcription.

study including 4224 patients with AML and 1517
patients with myelodysplastic syndrome, showed
that patients who develop aGVHD after transplant
have an increased risk of treatment-related mortality
and lower overall survival.3 Risk factors for GVHD
include intensive chemotherapy, previous viral infections, and advanced stage of leukemia.
The focus is on prevention of GVHD as an established disease remains notoriously difficult to treat.
There are many regimens in use to prevent GVHD
after allo-HCT, but in general they include combinations of agents that reduce T-cell activation
(cyclosporine, tacrolimus, sirolimus), reduce
T-cell proliferation (methotrexate, mycophenolate
mofetil), and cause T-cell depletion (antithymocyte globulin, post-transplant cyclophosphamide).4
Treatment options for an established disease are
limited, with steroids representing first line therapy
for aGVHD and cGVHD. Outcomes in patients
who do not respond to steroids are dismal, with
steroid-refractory aGVHD patients having a long
term survival rate of 5–30%.5 The first US Food
and Drug Administration (FDA) approvals in this
setting have come recently: ruxolitinib for steroidrefractory aGVHD (May 2019) and ibrutinib for
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steroid-refractory cGVHD (August 2017). An
array of other agents are currently undergoing preclinical and clinical trials.
The JAK/STAT system
Janus kinases (JAK) and signal transducers and
activation of transcription (STAT) were described
in the early 1990s as a family of rapid membrane
to nucleus signaling molecules that act downstream of over 50 cytokines.6 JAK kinases phosphorylate intracellular STAT family proteins in
response to extracellular signaling (Table 1).
Phosphorylated STATs then dimerize and translocate to the nucleus, where they bind to enhancers and promoters to regulate transcription of
target genes, predominantly without the need of
second messengers7 (Figure 1). There are four
members of the JAK family – JAK1, JAK2, JAK3,
and TYK2 – and seven members of the STAT
family – STAT1, STAT2, STAT3, STAT4,
STAT5a, STAT5b, and STAT6.8 Each JAK
kinase is activated by multiple cytokines, and
there is overlap in downstream effects.
Furthermore, STATs have overlapping and at
times competing effects on individual genes. An
example is the Bcl-2 gene, which is modulated by
STAT1 (which downregulates transcription) as
well as STAT3, STAT5, and STAT6 (which
upregulate transcription).9 It is possible that
blockade of one JAK or STAT protein may allow
dominant transcription modulation by another
member of the JAK/STAT system, and the ultimate physiologic effects are difficult to predict.
It has long been known that both loss-of-function
and gain-of-function mutations in the JAK/STAT
system can have profound phenotypic effects.10
JAK1 and JAK2 loss results in perinatal and embryonic lethality, respectively. Immunodeficiency syndromes are caused by both JAK3 loss (JAK3-SCID)
and TYK2, due to a lack of response to inflammatory cytokines including interferon gamma (IFNγ),
interferon alpha/beta (IFNα/β), interleukin (IL)-6,
IL-10, IL-12, and IL-23.11,12 Gain-of-function
mutations are associated with myeloproliferative
syndromes, including activating JAK2 in polycythemia vera, essential thrombocythemia, myelofibrosis, and hypereosinophilia.
Small molecule JAK inhibitors – or JAKinibs –
have varying specificity for the JAK kinases.13
Given the ubiquity of the JAK/STAT system in
inflammatory processes, modulation with JAKinibs
journals.sagepub.com/home/tah

EPO, erythropoietin; GM-CSF, Granulocyte-macrophage colony-stimulating factor; IFNα/β, interferon alpha/beta; IFNγ, interferon gamma; IL, interleukin; JAK, Janus kinases; MPL,
myeloproliferative leukemia virus oncogene; STAT, signal transducers and activation of transcription.

Figure 1. The JAK/STAT System. The JAK/STAT system is downstream of over 50 cytokine receptors. JAKs phosphorylate STATs, which then dimerize and translocate
to the nucleus where they regulate gene transcription. Promiscuity and redundancy exists at multiple levels, including promiscuity of cytokine receptors and DNA
STAT binding domains and overlap at the STAT phosphorylation level. Blockade of individual signaling elements may therefore have incomplete effects. Illustration
courtesy of Alessandro Baliani © (2019).
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Figure 2. The role of the JAK/STAT system in graft-versus-host disease. Top: Three step model of acute
GVHD. Bottom: Arrows with flat heads represent inhibition of JAKs by itacitinib (orange), ruxolitinib (red), and
baricitinib (green).

has been studied in various settings, including
rheumatologic disease,13,14 hematological malignancies,15,16 solid tumor malignancies,17 and septic
shock.18 Currently, there are a large number of
clinical trials involving JAK and STAT inhibitors
in all of these disease areas. JAKinibs with FDA
approvals or in clinical trials for hematologic diseases are partially listed in Table 2. Ruxolitinib is
FDA-approved for treatment of steroid-refractory
aGVHD. Baricitinib, itacitinib and ruxolitinib are
undergoing clinical trials for treatment or prevention of aGVHD or cGVHD GVHD.
The remainder of this review focuses on the pathophysiology of aGVHD and cGVHD. Within each

4

section, we will discuss the evidence for JAK/
STAT system involvement as well as effects of
inhibition (Figure 2).
Acute GVHD: three step model
aGVHD is traditionally characterized as a three
step process: (a) tissue damage from disease and
conditioning chemoradiotherapy, (b) donor
T-cell activation, and (c) recruitment and activation of other immune cells.19 The JAK/STAT
pathways are active in each step.20 The pathophysiology of each step is reviewed separately
below, with a focus on evidence for JAK/STAT
involvement and utility of pathway inhibition.

journals.sagepub.com/home/tah

R Abboud, J Choi et al.
Table 2. JAK/STAT inhibitors for hematologic diseases (GVHD indications highlighted).
Drug

Target of
inhibition

Disease setting

Clinical phase

Fedratinib

JAK2

Myelofibrosis

FDA Approved

Ruxolitinib

JAK1/JAK2

Myelofibrosis

FDA Approved

Polycythemia Vera

FDA Approved

Steroid Refractory Acute GVHD

FDA Approved

Rheumatoid Arthritis

FDA Approved

Chronic GVHD

Phase II (NCT02759731)

Prevention of acute GVHD

Phase I (NCT04131738)

FDA Approved:

Baricitinib

JAK1/JAK2
>JAK3/TYK2

Under Clinical Investigation:
Baricitinib

JAK1/JAK2
>JAK3, TYK2

Cerdulatinib

SYK/JAK

Non-Hodgkin lymphoma

Phase II (NCT01994382, NCT04021082)

Gandotinib

JAK2

Myeloproliferative neoplasms

Phase II (NCT01594723)

Itacitinib

JAK1

Prevention of acute GVHD

Phase I (NCT03320642, NCT03755414)
Phase II (NCT04127721)

Acute GVHD

Phase I (NCT04070781, NCT03497273)
Phase II (NCT03846479, NCT03721965)

Chronic GVHD

Phase II (NCT04200365)
Phase III (NCT03584516)

Prevention of Cytokine Release Syndrome

Phase I (NCT04071366, NCT03755414)

Hodgkin Lymphoma

Phase II (NCT03697408)

Myelofibrosis

Phase II (NCT03144687)

Acute Lymphocytic Leukemia

Phase I (NCT03989466)

Lestaurtinib

JAK2

Acute myeloid leukemia

Phase II (NCT02428543)

Momelotinib

JAK1/JAK2

Myeloproliferative neoplasms

Phase III (NCT04173494)

Pacritinib

JAK2

Prevention of GVHD

Phase II (NCT02891603)

Myeloproliferative neoplasms

Phase II (NCT03645824)

Lymphoproliferative Disorders

Phase I (NCT03601819)

Acute myeloid leukemia, Acute lymphoblastic
leukemia, Acute GVHD, Chronic GVHD, Chronic
myeloid leukemia, Hodgkin lymphoma, NonHodgkin Lymphoma, Hypereosinophilic disorders

Total 76 studies recruiting subjects.
Eight studies recruiting in acute or
chronic GVHD.

Ruxolitinib

JAK1/JAK2

FDA, US Food and Drug Administration; GVHD, graft-versus-host disease; JAK, Janus kinases; STAT, signal transducers and activation of
transcription.

journals.sagepub.com/home/tah
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Phase I: tissue damage
Prior to allo-HCT, conditioning chemoradiotherapy causes tissue damage, inducing a systemic
inflammatory state. Inflammatory cytokines such
as TNFα and IL-1 are released, and higher levels
are associated with GVHD.21 Higher intensity of
conditioning has also been associated with more
severe GVHD in both animal models and human
studies.22,23 There are a number of innate and
adaptive mechanisms through which tissue injury
leads to immune activation, and many signal
through the JAK/STAT system.24
Damage-associated molecular patterns. Damageassociated molecular patterns (DAMPs) are endogenous biomolecules, including ATP, HMGB1, uric
acid and heat shock proteins that are released in the
context of tissue injury. They lead to immune activation through an array of pathways, including tolllike receptors (TLRs),25 NLRP326 and STAT1.27
STAT1, specifically, may be a particularly important mediator of GVHD. In preclinical models in
which STAT1 is knocked out in CD4+ T-cells,
T-regulatory expansion is promoted and GVHD is
reduced.28 STAT1 is downstream of two cytokine
receptors, the IFNγ and IFNα/β receptors.29 These
cytokines are known mediators of GVHD.28,30 The
IFNγ and IFNα/β receptors signal through JAK1/
JAK2 and JAK1/TYK2, respectively.29,31 Targeting
GVHD at both the level of the IFNγ receptor and
the JAK1/JAK2 level has been successful, and the
combination may be synergistic. In murine alloHCT models, inhibition of this axis with IFNγ-R
blockers or JAKinibs alone or in combination prevents GVHD.28,30,32
Pathogen-associated molecular patterns and the
gut microbiome. Pathogen-associated molecular
patterns (PAMPs) are exogenous biomolecules,
including bacterial lipopolysaccharides (LPSs).
Gut injury from conditioning chemoradiotherapy increases translocation of bacteria, leading
to release of PAMPs into tissue and blood. In
step 3 of aGVHD (below), PAMPs activate
primed antigen-presenting immune cells through
TLRs. Therefore, the role of the gut microbiome
in GVHD has long been an active area of
research. Recently, rapid progress has been made
possible by modern bacterial genome sequencing technologies. Pre-transplant microbiome
diversity is associated with reduced mortality,
and loss of diversity – worsened by prophylactic
antibiotics and total parenteral nutrition (TPN)
– is associated with increased GVHD and
6

mortality.33,34 Furthermore, certain bacteria may
be protective against GVHD, including Lactobacillus and Blautia genus. TLR activation by bacterial LPS induces Notch signaling in monocytes,
which can be abrogated by STAT3 inhibition.35
STAT3 is downstream of the IL-6 receptor. This
may represent an opportunity to break the positive feedback loop between steps one and three
in the development of aGVHD. Consistent with
this concept, several groups have shown promising clinical results targeting this signaling axis
with tocilizumab, an IL-6 receptor blocking antibody, to prevent aGVHD.36,37
Macrophages and neutrophils. Neoangiogenesis
and gastrointestinal infiltration by macrophages
and neutrophils are among the earliest events in
GVHD.5 Macrophages residing in target tissues
secrete significant amounts of nitric oxide, causing
direct tissue damage and inhibition of epithelial
stem cell proliferation. Macrophage production
of nitric oxide occurs through cooperative
JAK2/STAT3 and PI3-K signaling.38 Neutrophils
are recruited to the gastrointestinal tract by
DAMPs and PAMPs, enhancing aGVHD through
tissue damage.39 Granulocyte-macrophage colonystimulating factor-activated neutrophils signal

through the JAK2/STAT3 and STAT5b axis.40
Whether macrophage and neutrophil activity in
GVHD can be prevented by targeting the JAK/
STAT system is an ongoing area of research.
Phase II: donor T-cell activation
This state of systemic inflammation leads to an
increase in major histocompatibility complex
(MHC) expression by antigen-presenting cells
(APCs) at the time of donor cell infusion. This leads
to phase II in aGVHD: donor T-cell activation.
After infusion, donor T-cell receptors recognize
allo-antigens presented on MHC molecules by
host (direct) or donor (indirect) antigen presenting cells. This leads to rapid donor T-cell activation and secretion of an array of cytokines,
including IL-2, IL-15 and IFNγ. Multiple models
have demonstrated the correlation between
elevated IFNγ signaling and GVHD. The dose
effect of IL-2, however, has been less clear.
Administration of low dose IL-2 increases the
severity of GVHD in preclinical models,41 however high doses of IL-2 are protective in others,42
perhaps through inhibition of IFNγ signaling.43 A
phase I–II clinical trial of an anti-IL-2 receptor
journals.sagepub.com/home/tah
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antibody for steroid refractory aGVHD showed
some responses,44 but this approach has not been
taken forward in additional clinical trials.
Trafficking of activated donor T-cells to target
organs is an essential step in the development of
aGVHD. In response to activation by APCs,
T-cells secrete IFNγ and initiate signaling through
the IFNγ-receptor and JAK/STAT system.28 This
results in increased T-cell expression of CXCR3,
leading to T-cell trafficking to the gut, liver, and
skin.28 This trafficking is reduced in IFNγreceptor- or CXCR3-knockout models, and both
trafficking and GVHD are reduced by JAKinibs
in mouse models.28,30,45 Furthermore, dual inhibition of the IFNγ-receptor and IL-6-receptor,
both genetically and pharmacologically, completely prevents aGVHD in murine models.30
Phase III: recruitment and activation
of immune cells
Phase III of aGVHD involves recruitment of
other cell types and propagation of tissue damage
through cellular and inflammatory effectors.
Effector T-cells. Activated cytotoxic T-cells (CTLs)
induce apoptosis of host tissues through multiple
pathways. CD8+ CTLs predominantly use the perforin/granzyme pathway, while CD4+ CTLs use
the Fas/Fas ligand pathway. Both pathways are
important in aGVHD, and murine models deficient
in either perforin-dependent killing or Fas ligand
still develop GVHD, with differential severity in target tissues.30,46 IFNγ increases Fas ligand expression
on CD4+ CTLs.47 Granzyme has different roles in
GVHD and GVL, depending on the T-cell subset.
For example, the lack of granzyme in the CD8 subset cells prevents GVHD and augments GVL, while
the lack of granzyme in the CD4 subset cells aggravates GVHD and impairs GVL.48–50
B-cells. While T-cells have long been regarded as
the main regulators of aGVHD and cGVHD, the
role of B-cells has recently been examined more
closely.51–57 B-cells are central to adaptive immune
response, specializing in memory responses, antigen presentation and the formation of antibodies
against foreign bacteria, viruses and peptide antigens. Cytokines classically attributed to B-cells
include IL-6, TNFα and IL-10. In addition,
B-cells can secrete IL-2, IFNγ, IL-12 and IL-4,
causing differentiation of naïve T-cells into TH1
and TH2 effector subtypes.55 Other B-cell subsets
journals.sagepub.com/home/tah

have immunosuppressive functions and can
induce anergy and T-cell deletion.52–54
Preclinical studies with B-cell targeting therapies
for GVHD have shown opposing results, consistent with the ability of B-cells to either promote or
inhibit cytotoxic T-cell function. aGVHD is
reduced in B-cell deficient mice receiving mismatched B-cell depleted grafts.58 However, host
B-cells can suppress GVHD through IL-10 secretion, and removing this B-cell-derived IL-10
through killing or gene editing B-cells leads to
more severe aGVHD.51
Likewise, clinical experiences with anti-CD20
therapies have had mixed results. One report
included patients treated with rituximab as part
of conditioning, and rates of aGVHD were
encouraging.59 A randomized phase II trial compared four doses of rituximab at day +21 then at
day +175 with untreated patients showed no difference in aGVHD between the two groups. A
third report described the use of rituximab in
patients with steroid-refractory aGVHD with
occasional complete responses observed.59
Together, these reports indicate that B-cell depletion may have a role in prophylaxis against
aGVHD if used early in the peri-transplant period
and also in the frontline treatment of aGVHD.
There is rationale for targeting the JAK/STAT system to modulate B-cell activity. Stimulation of the
B-cell Receptor (BCR) leads to downstream phosphorylation of multiple STATs, including STAT1,
STAT3 and STAT5.57 STAT phosphorylation can
occur in both JAK-dependent and-independent
manners. In a B-cell line, BCR activation by the Src
kinase Lyn causes JAK-independent STAT phosphorylation, which is not inhibited by loss of JAK1
and JAK2 activity.60 In contrast, in chronic lymphocytic leukemia cells, BCR stimulation by anti-human
IgM antibody caused STAT3 phosphorylation and
shuttling to the nucleus.61 This effect was blocked by
JAK1/2 inhibition with ruxolitinib, but not by Lyn
kinase blockade with dasatinib.61 Therefore, the type
and magnitude of BCR stimulation affects whether
STAT3 signaling occurs in a JAK/STAT-dependent
or -independent manner. The effect of JAKinibs on
B-cells in the context of human aGVHD is a current
area of investigation.
Natural killer cells. Natural killer (NK) cells are the
first donor-derived lymphocyte subset to recover
after allo-HCT. Similar to B-cells, NK cells can
7
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both inhibit and promote GVHD, depending on the
physiologic milieu, as well as the specific NK cell
subtype.62 Transplantation of activated human NK
cells into SCID mice induces GVHD.63 Conversely,
in a phase I trial, memory-like NK cells from haploidentical donors showed anti-leukemia activity in
recipients without causing GVHD.64 The proGVHD effects of NK cells are mediated through
inflammatory cytokines including IL-2, IFNγ and
TNFα, which signal through the JAK/STAT system. Furthermore, disruption of these pathways can
reduce cytotoxicity of NK cells in preclinical models. In a murine sarcoma model, TRAIL-mediated
NK cell cytotoxicity was dependent on IFNγ.65 In
multiple independent models, disruption of the
IL-12/STAT4 axis through STAT4 deletion leads to
impaired cytotoxicity of NK cells.66,67 The role of
NK cells in GVHD, and the effects of JAKinibs on
NK cells, are active areas of investigation. In patients
with aGVHD treated with the JAK1 inhibitor itacitinib, those with signs of overactive NK cell activity
had a higher response rate.68
Chronic GVHD
While cGVHD is a distinct syndrome from
aGVHD, they share many immunologic underpinnings through which APC interactions with alloreactive T-cells lead to an immune response against
recipient tissue.69,70 Features distinct to cGVHD
include insufficient central tolerance due to thymic
dysfunction, insufficient peripheral tolerance due
to T-regulatory dysfunction and tissue fibrosis.
The role of the JAK/STAT pathway is an area
of current investigation. Ruxolitinib therapy
reduces the number of circulating activated
T (CD3+HLA-DR+) cells in patients with
cGVHD.71 There are other novel T-cell signaling
pathways that have been implicated in cGVHD.
Recently, the Rho-associated kinase 2 (ROCK2)
inhibitor KD025 was shown to reduce cGVHD
end organ damage and induce a shift from T follicular helper cells to T follicular regulatory cells.
There was a reduction in STAT3 and an increase
in STAT5 phosphorylation.72 The role of ROCK2
was subsequently described as a feed-forward signal potentiating STAT3-related gene transcription
through a ROCK2/STAT3/JAK2 complex.73 A
clinical trial evaluating the safety and activity of
KD025 in patients with cGVHD is underway
(Clinical Trials.gov Identifier: NCT02841995).
B-cell activity is important in cGVHD, and the evidence for JAK/STAT involvement in B-cell signaling is discussed above. Ibrutinib, a Bruton’s
8

tyrosine kinase (BTK) inhibitor that inhibits B-cell
activity, was FDA approved for steroid refractory
cGVHD in 2017 based on the PCYC-1129-CA
study showing a response rate of 67%.74 Ibrutinib
is being evaluated in a phase III study as frontline
therapy for cGVHD (Clinical Trials.gov Identifier:
NCT02959944).
Clinical evidence of JAK/STAT inhibition for
prevention and treatment of GVHD
JAK inhibition for the prevention and treatment
of GVHD is an extremely active area of study.
There are many open and recruiting clinical trial
in this area (Table 2). A number of clinical trials
have completed with results reported. One of
these has led to an FDA approval.
Ruxolitinib, a JAK1/2 inhibitor, gained FDA
approval in May 2019 for the treatment of steroidrefractory aGVHD. In the REACH1 trial, a single
arm phase II study, the overall response rate for
ruxolitinib in patients with steroid-refractory
aGVHD was 55% by day 28 and 73% at any time.
Responses were fast (median day 7) and durable
(median duration of response 345 days) and
occurred in lung, liver, intestines and skin.75
Ruxolitinib was shown to reduce levels of soluble
IL-2 receptor, IL-6, and IFNγ.71,76 Of note, only
5.6% of patients had relapse of disease. Patients did
experience hematologic toxicity, with cytopenias
seen in all three lines. Infectious complications
included cytomegalovirus, sepsis, and bacteremia.
In another disease, a pilot study investigating the
use of ruxolitinib for GVHD prophylaxis in patients
with myelofibrosis undergoing allo-HCT has completed recruitment (Clinical Trials.gov Identifier:
NCT02806375), with interval results indicating
feasibility of the approach, although therapy may
be associated with delayed engraftment.15
Itacitinib, a JAK1 inhibitor, is being studied for
the treatment of aGVHD and cGVHD. A phase
I study of itacitinib in patients with aGVHD
revealed overall response rates of 83% and
64% respectively for treatment of naïve and
steroid-refractory patients. Unfortunately, the
Gravitas-301 phase III study evaluating itacitinib
in combination with corticosteroids in patients
with treatment-naïve aGVHD failed to meet its
primary (overall response rate at say 28) and secondary (non-relapse mortality at 6 months) endpoints (Incyte Press Release 1/2/2020). The
GRAVITAS-309 phase III study is currently
journals.sagepub.com/home/tah
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evaluating itacitinib with corticosteroids versus
corticosteroids alone as first-line treatment for
moderate or severe cGVHD. Itacitinib is also
being evaluated for prevention of aGVHD after
haplo-HCT (Clinical Trials.gov Identifier:
NCT03755414) and after cellular therapies
(Clinical Trials.gov Identifier: NCT04071366).
Baricitinib is under investigation for the prevention of GVHD (Clinical Trials.gov Identifier:
NCT04131738) and the treatment of cGVHD
(Clinical Trials.gov Identifier: NCT02759731).
Pacritinib is under investigation for the prevention of GVHD (Clinical Trials.gov Identifier:
NCT02891603).
Interleukin 6, which is upstream of JAK1, JAK2,
and STAT3, is upregulated after allo-HCT. Two
groups have conducted early stage trials integrating
the IL-6 receptor blocking agent tocilizumab into
GVHD prophylaxis. The first trial used cyclosporine, methotrexate, and tocilizumab: the day
100 incidence of grade 2–4 aGVHD was 12%
(95% CI 5–24) and the incidence of grade 3–4
aGVHD was 4% [95% confidence interval (CI)
1–13].37 The second trial used tacrolimus, methotrexate, and tocilizumab, and the cumulative incidences of grades II–IV and III–IV aGVHD were
14% (95% CI 5–30) and 3% (95% CI 0–11) at day
100.36 Both trials reported a reduction in aGVHD
of the GI tract, consistent with known IL-6 signaling involvement in T-cell trafficking to the gut.28
There are two trials currently recruiting patients
(Clinical Trials.gov Identifiers: NCT03699631
and NCT03434730) examining the role of tocilizumab to prevent GVHD after all-HCT.
Toxicity of long-term use of JAK inhibitors
As more patients are treated with JAK inhibitors
for extended periods of time, a close eye must be
kept on long-term toxicities. Much of the longterm safety data comes from the rheumatology
literature, where JAK inhibitors are used as diseasemodifying therapies.77 There is, however, growing experience using long-term JAK inhibition in
myeloproliferative neoplasms. These data suggest
there may be an increased incidence of cutaneous
malignancies and infections.
In the COMFORT-II phase III trial of ruxolitinib
versus best available therapy for myelofibrosis,
17% of patients treated with ruxolitinib developed non-melanoma skin cancers, compared with
journals.sagepub.com/home/tah

2.7% in the control group.78 Furthermore, a
recent case series described five cases of aggressive skin cancers – including one lentigo maligna
melanoma and one metastatic undifferentiated
pleomorphic sarcoma – in patients with myelofibrosis on ruxolitinib.79 In contrast, patients with
rheumatoid arthritis (RA) treated with tofacitinib
or baricitinib did not appear to be at increased
risk of cutaneous malignancies or lymphoma.
Patients with RA have a lower risk of malignancy
than the general population, which may underpin
some of this conflicting data.
A number of infectious complications appear to
be increased in patient treated with JAK inhibitors. Herpes zoster infections are more common
in patients treated tofacitinib, baricitinib, and
ruxolitinib.77,80 There may also be a mild increase
in pulmonary and urinary tract infections. In
patients with GVHD, who are profoundly immunosuppressed and frequently suffer from infections, it may be especially difficult to determine
the effect of JAK inhibition on infection rates.
These long-term complications may be specifically relevant to patients with cGVHD. JAK inhibition for prevention of GVHD or treatment of
aGVHD may be of sufficiently limited duration,
thus minimizing these toxicities.
Conclusion
The JAK/STAT signaling pathways have both
inflammatory and immunoregulatory effects.
JAKinibs with different JAK specificities and
inhibitory capacities have the potential to produce very different clinical results. Both the dose
and specificity of JAKinibs are important in determining clinical outcomes, with different diseases
demanding different profiles of inhibition for
optimal therapeutic activity. Both baricitinib and
ruxolitinib are regarded as JAK1/2 inhibitors, yet
there are significant differences in their effect on
both GvL and GVHD.30 Indeed, there is evidence
that GvL and GVHD could be uncoupled with
the right approach. In a murine mismatched alloHCT model, baricitinib caused greater GVHD
reduction compared with ruxolitinib, with paradoxical improvement in GvL.30 Baricitinib causes
less inhibition of STAT5 phosphorylation, and
STAT5 plays a role in regulatory T-cell expansion, which in turn may suppress GVHD.14,30,81,82
This underscores the importance of dosing and
specificity of JAKinibs in optimizing clinical
9
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outcomes for patients. This is exemplified in
another systemic inflammatory disease: sepsis. In
a mouse model of Candida sepsis, an intermediate dose of ruxolitinib led to superior survival
compared with both high and low doses.18 Fungal
burden was highest in mice treated with high
doses of ruxolitinib, implying that death was dictated by immune over-suppression. This immune
suppression, in the context of allo-HCT or cellular therapies, could reduce GvL or immune mediated tumor killing, respectively. Altogether, these
data signal that the type and dose of JAK inhibition will dictate clinical outcomes, and great care
must be taken in both JAKinib selection and timing of intervention.
These data support a “Goldilocks Effect” - both
too little and too much JAK/STAT inhibition
being suboptimal for the prevention and treatment of GVHD in the context of allo-HCT for
malignant hematologic conditions. Immune oversuppression could lead to higher rates of relapse
and lower rates of engraftment. Immune undersuppression could lead to a higher rate and severity of GVHD. JAKinibs may represent a new tool
in balancing GVL and GVHD, allowing a customized approach for each patient based on disease status and comorbidities.
Author contributions
RA and JFD wrote the first version of the manuscript. JC, PR, MAS, and CNA wrote subsequent
versions of the manuscript.
Conflict of interest statement
RA, JC, PR, MAS, CNA, and JFD have employment/salary from Washington University in St.
Louis. JC has received research funding from
Mallinckrodt Pharmaceuticals, served as a consultant for Daewoong Pharmaceutical, and received
honorarium from Incyte Corporation. MAS has
the following consulting/advisory committees:
Amgen, Astellas, Dova pharmaceuticals, FlatIron
Inc, Incyte, Partners Therapeutics, Pfizer, Sanofi
Genzyme, Abbvie, Merck, Takeda. CNA has the
following consulting/advisory committees: Bayer,
Incyte, Jazz Pharma, NKarta, Novartis, Pfizer,
Seattle Genetics, Tetraphase Pharmaceuticals.
JFD has the following consulting/advisory committees: Rivervest, Bioline, Amphivena, Incyte,
NeoImuneTech, Macrogenics, and ownership
investment: Magenta, WUGEN. The authors
have no other conflicts relevant to this
publication.
10

Funding
The authors disclosed receipt of the following
financial support for the research, authorship,
and/or publication of this article: RA is supported
by the American Society of Hematology Clinical
Research Training Institute and the National
Cancer Institute of the National Institutes of
Health under Award Number R25 CA190190.
JFD is supported by NIH/NCI: 1 P50 CA171963,
(PI: Link, Project 4 Leader: DiPersio) and NIH/
NCI: R35 1R35CA210084 NCI (PI: DiPersio).
ORCID iD
Ramzi Abboud
7786-4155

https://orcid.org/0000-0001-

References
1. Warren EH. Biology of the human graft-versustumor response and how to exploit it. In: Stephen
Forman J, Negrin RS, Antin JH, et al. (eds)
Thomas’ hematopoietic cell transplantation. 5th ed.
Chichester, UK: John Wiley & Sons, Ltd., 2016,
pp. 166–181.
2. Horowitz MM, Gale RP, Sondel PM, et al. Graftversus-leukemia reactions after bone marrow
transplantation. Blood 1990; 75: 555–562.
3. Weisdorf D, Zhang MJ, Arora M, et al. Graftversus-host disease induced graft-versusleukemia effect: greater impact on relapse and
disease-free survival after reduced intensity
conditioning. Biol Blood Marrow Transplant
2012; 18: 1727–1733.
4. Chao NJ. Pharmacologic prevention of acute
graft-versus-host disease. In: Stephen Forman
J, Negrin RS, Antin JH, et al. (eds) Thomas’
hematopoietic cell transplantation. Chichester, UK:
John Wiley & Sons, Ltd., 2016, pp. 990–1006.
5. Zeiser R and Blazar BR. Acute graft-versus-host
disease — biologic process, prevention, and
therapy. N Engl J Med 2017; 377: 2167–2179.
6. Villarino AV, Kanno Y and O’Shea JJ.
Mechanisms and consequences of JAK-STAT
signaling in the immune system. Nat Immunol
2017; 18: 374–384.
7. Aaronson DS and Horvath CM. A road map for
those who don’t know JAK-STAT. Science 2002;
296: 1653–1655.
8. Darnell JE, Kerr IM and Stark GR. JAK-STAT
pathways and transcriptional activation in
response to IFNs and other extracellular signaling
proteins. Science 1994; 264: 1415–1421.

journals.sagepub.com/home/tah

R Abboud, J Choi et al.
9. Bousoik E and Montazeri Aliabadi H. “Do We Know
Jack” about JAK? A closer look at JAK/STAT
signaling pathway. Front Oncol 2018; 8: 1–20.

develop acute GVHD. Bone Marrow Transplant
1995; 15: 99–104.

10. Villarino AV, Kanno Y and O’Shea JJ.
Mechanisms and consequences of JAK–STAT
signaling in the immune system. Nat Immunol
2017; 18: 374–384.

22. Hill GR, Crawford JM, Cooke KR, et al. Total
body irradiation and acute graft-versus-host
disease: the role of gastrointestinal damage
and inflammatory cytokines. Blood 1997; 90:
3204–3213.

11. Kreins AY, Ciancanelli MJ, Okada S, et al.
Human TYK2 deficiency: mycobacterial and
viral infections without hyper-IgE syndrome.
J Exp Med 2015; 212: 1641–1662.

23. Nakasone H, Fukuda T, Kanda J, et al. Impact of
conditioning intensity and TBI on acute GVHD
after hematopoietic cell transplantation. Bone
Marrow Transplant 2015; 50: 559–565.

12. Nemoto M, Hattori H, Maeda N, et al.
Compound heterozygous TYK2 mutations
underlie primary immunodeficiency with T-cell
lymphopenia. Sci Rep 2018; 8: 1–13.

24. Magenau J, Runaas L and Reddy P. Advances in
understanding the pathogenesis of graft-versushost disease. Br J Haematol 2016; 173: 190–205.

13. Fragoulis GE, Mcinnes IB and Siebert S. JAKinhibitors. New players in the field of immunemediated diseases, beyond rheumatoid arthritis.
Rheumatology (Oxford) 2019; 58: i43–i54.
14. O’Shea JJ and Plenge R. JAK and STAT
signaling molecules in immunoregulation and
immune-mediated disease. Immunity 2012; 36:
542–550.
15. Morozova EV, Moiseev IS, Barabanshikova
MV, et al. Graft-versus-host disease prophylaxis
with posttransplantation cyclophosphamide and
ruxolitinib in patients with myelofibrosis. Blood
2017; 130(Suppl. 1): 4492.
16. Jagasia M, Zeiser R, Arbushites M, et al.
Ruxolitinib for the treatment of patients with
steroid-refractory GVHD: an introduction to the
REACH trials. Immunotherapy 2018; 10: 391–402.
17. Buchert M, Burns CJ and Ernst M. Targeting
JAK kinase in solid tumors: emerging
opportunities and challenges. Oncogene 2016; 35:
939–951.
18. Tsirigotis P, Papanikolaou N, Elefanti A, et al.
Treatment of experimental Candida sepsis with a
Janus Kinase inhibitor controls inflammation and
prolongs survival. Antimicrob Agents Chemother
2015; 59: 7367–7373.
19. Ferrara J and Antin J. The Pathophysiology
of Graft-versus-Host Disease. In: Stephen
FJ, Negrin RS, Antin JH, et al. (eds) Thomas’
hematopoietic cell transplantation. Chichester, UK:
John Wiley & Sons Ltd., 2016, pp. 146–152.
20. Schroeder MA, Choi J, Staser K, et al. The role
of janus kinase signaling in graft-versus-host
disease and graft versus leukemia. Biol Blood
Marrow Transplant 2018; 24: 1125–1134.
21. Remberger M, Ringden O and Markling L. TNF
alpha levels are increased during bone marrow
transplantation conditioning in patients who

journals.sagepub.com/home/tah

25. Brennan TV, Lin L, Huang X, et al. Heparan
sulfate, an endogenous TLR4 agonist, promotes
acute GVHD after allogeneic stem cell
transplantation. Blood 2012; 120: 2899–2908.
26. Jankovic D, Ganesan J, Bscheider M, et al. The
Nlrp3 inflammasome regulates acute graft-versushost disease. J Exp Med 2013; 210: 1899–1910.
27. Wilhelm K, Ganesan J, Müller T, et al. Graftversus-host disease is enhanced by extracellular
ATP activating P2X7R. Nat Med 2010; 16:
1434–1439.
28. Choi J, Ziga ED, Ritchey J, et al. IFNγR signaling
mediates alloreactive T-cell trafficking and
GVHD. Blood 2012; 120: 4093–4103.
29. Murray PJ. The JAK-STAT signaling pathway:
input and output integration. J Immunol 2007;
178: 2623–2629.
30. Choi J, Cooper ML, Staser K, et al. Baricitinibinduced blockade of interferon gamma receptor
and interleukin-6 receptor for the prevention and
treatment of graft-versus-host disease. Leukemia
2018; 32: 2483–2494.
31. Yoon P, Keylock KT, Hartman ME, et al.
Macrophage hypo-responsiveness to interferon-γ
in aged mice is associated with impaired signaling
through JAK-STAT. Mech Ageing Dev 2004; 125:
137–143.
32. Choi J, Cooper ML, Alahmari B, et al.
Pharmacologic blockade of JAK1/JAK2 reduces
GvHD and preserves the graft-versus-leukemia
effect. PLoS One 2014; 9: 2–7.
33. Jenq RR, Ubeda C, Taur Y, et al. Regulation of
intestinal inflammation by microbiota following
allogeneic bone marrow transplantation. J Exp
Med 2012; 209: 903–911.
34. Holler E, Butzhammer P, Schmid K, et al.
Metagenomic analysis of the stool microbiome
in patients receiving allogeneic stem cell
transplantation: loss of diversity is associated with

11

Therapeutic Advances in Hematology 11
use of systemic antibiotics and more pronounced
in gastrointestinal graft-versus-host disease. Biol
Blood Marrow Transplant 2014; 20: 640–645.

reduces experimental murine acute GVHD while
preserving GVT effects. Clin Cancer Res 2015; 21:
3740–3749.

35. Hildebrand D, Uhle F, Sahin D, et al. The
interplay of notch signaling and STAT3 in TLRactivated human primary monocytes. Front Cell
Infect Microbiol 2018; 8: 1–12.

46. Baker MB, Altman NH, Podack ER, et al. The
role of cell-mediated cytotoxicity in acute GVHD
after MHC-matched allogeneic bone marrow
transplantation in mice. J Exp Med 1996; 183:
2645–2656.

36. Drobyski WR, Szabo A, Zhu F, et al.
Tocilizumab, tacrolimus and methotrexate for the
prevention of acute graft-versus-host disease: low
incidence of lower gastrointestinal tract disease.
Haematologica 2018; 103: 717–727.
37. Kennedy GA, Varelias A, Vuckovic S, et al.
Addition of interleukin-6 inhibition with
tocilizumab to standard graft-versus-host
disease prophylaxis after allogeneic stem-cell
transplantation: a phase 1/2 trial. Lancet Oncol
2014; 15: 1451–1459.
38. Alblas J, Honing H, De CR, et al. Signal
regulatory protein alpha ligation induces
macrophage nitric oxide production through JAK/
STAT- and phosphatidylinositol 3-kinase/Rac1/
NAPDH oxidase/H2O2-dependent pathways.
Mol Cell Biol 2005; 25: 7181–7192.
39. Schwab L, Goroncy L, Palaniyandi S, et al.
Neutrophil granulocytes recruited upon
translocation of intestinal bacteria enhance graftversus-host disease via tissue damage. Nat Med
2014; 20: 648–654.
40. Al-shami A and Naccache PH. Granulocytemacrophage colony-stimulating factor-activated
signaling pathways in human neutrophils. J Biol
Chem 1999; 274: 5333–5338.
41. Malkovský M, Brenner MK, Hunt R, et al. T-cell
depletion of allogeneic bone marrow prevents
acceleration of graft-versus-host disease induced
by exogenous interleukin 2. Cell Immunol 1986;
103: 476–480.
42. Sykes M, Hoyles KA, Romick ML, et al. In vitro
and in vivo analysis of bone marrow-derived
CD3+, CD4–, CD8–, NK1.1+ cell lines. Cell
Immunol 1990; 129: 478–493.
43. Szebeni J, Wang MG, Pearson DA, et al.
IL-2 inhibits early increases in serum gamma
interferon levels associated with graft-versus-hostdisease. Transplantation 1994; 58: 1385–1393.
44. Anasetti C, Martin PJ, Hansen JA, et al. A
phase I–II study evaluating the murine anti-IL-2
receptor antibody 2A3 for treatment of acute
graft-versus-host disease. Transplantation 1990;
50: 49–54.
45. Carniti C, Gimondi S, Vendramin A, et al.
Pharmacologic inhibition of JAK1/JAK2 signaling

12

47. Ueno Y, Ishii M, Yahagi K, et al. Fas-mediated
cholangiopathy in the murine model of graft versus
host disease. Hepatology 2000; 31: 966–974.
48. Du W, Leigh ND, Bian G, et al. Granzyme B
contributes to the optimal graft-versus-tumor
effect mediated by conventional CD4+ T cells.
J Immunol Res Ther 2016; 1: 22–28.
49. Du W, Leigh ND, Bian G, et al. Granzyme
B–mediated activation-induced death of CD4+
T cells inhibits murine acute graft-versus-host
disease. J Immunol 2015; 195: 4514–4523.
50. Bian G, Ding X, Leigh ND, et al. Granzyme
B–mediated damage of CD8+ T cells impairs
graft-versus-tumor effect. J Immunol 2013; 190:
1341–1350.
51. Rowe V, Banovic T, MacDonald KP, et al. Host
B cells produce IL-10 following TBI and attenuate
acute GVHD after allogeneic bone marrow
transplantation. Blood 2006; 108: 2485–2492.
52. Bennett SR, Carbone FR, Toy T, et al. B cells
directly tolerize CD8+ T cells. J Exp Med 1998;
188: 1977–1983.
53. Höllsberg P, Batra V, Dressel A, et al. Induction
of anergy in CD8 T cells by B cell presentation
of antigen. J Immunol 1996; 157: 5269–5276.
54. Tretter T, Venigalla RK, Eckstein V, et al.
Induction of CD4+ T-cell anergy and apoptosis
by activated human B cells. Blood 2008; 112:
4555–4564.
55. Harris DP, Haynes L, Sayles PC, et al. Reciprocal
regulation of polarized cytokine production by effector
B and T cells. Nat Immunol 2000; 1: 475–482.
56. Shimabukuro-Vornhagen A, Hallek MJ, Storb
RF, et al. The role of B cells in the pathogenesis
of graft-versus-host disease. Blood 2009; 114:
4919–4927.
57. Papin JA and Palsson BO. The JAK-STAT
signaling network in the human B-cell: an
extreme signaling pathway analysis. Biophys J
2004; 87: 37–46.
58. Schultz KR, Paquet J, Bader S, et al.
Requirement for B cells in T cell priming
to minor histocompatibility antigens and

journals.sagepub.com/home/tah

R Abboud, J Choi et al.
development of graft-versus-host disease. Bone
Marrow Transplant 1995; 16: 289–295.
59. Christopeit M, Schütte V, Theurich S, et al.
Rituximab reduces the incidence of acute graftversus-host disease. Blood 2009; 113: 3130–3131.
60. Wang L, Kurosaki T and Corey SJ. Engagement
of the B-cell antigen receptor activates STAT
through Lyn in a Jak-independent pathway.
Oncogene 2007; 26: 2851–2859.
61. Rozovski U, Wu JY, Harris DM, et al. Stimulation
of the B-cell receptor activates the JAK2/STAT3
signaling pathway in chronic lymphocytic leukemia
cells. Blood 2014; 123: 3797–3802.
62. Simonetta F, Alvarez M and Negrin RS. Natural
killer cells in graft-versus-host-disease after
allogeneic hematopoietic cell transplantation.
Front Immunol 2017; 8: 465.
63. Xun C, Brown SA, Jennings CD, et al. Acute
graft-versus-host-like disease induced by
transplantation of human activated natural killer
cells into SCID mice. Transplantation 1993; 56:
409–417.
64. Romee R, Rosario M, Berrien-Elliott MM, et al.
Cytokine-induced memory-like natural killer
cells exhibit enhanced responses against myeloid
leukemia. Sci Transl Med 2016; 8: 357ra123.
65. Takeda K, Smyth MJ, Cretney E, et al. Critical role
for tumor necrosis factor-related apoptosis-inducing
ligand in immune surveillance against tumor
development. J Exp Med 2002; 195: 161–169.
66. Kaplan M, Sun YL, Hoey T, et al. Impaired
IL-12 responses and enhanced development of
Th2 cells in Stat4-deficient mice. Nature 1996;
382: 174–177.
67. Thierfelder WE, van Deursent JM, Yamamoto
K, et al. Requirement for Stat4 in interleukin-12mediated responses of natural killer and T cells.
Nature 1996; 382: 171–174.
68. Staser K, Choi J, Khoury J, et al. 21-color flow
cytometry reveals immunophenotypes associated with
response in acute graft-versus-host disease (aGVHD)
patients treated with the Janus kinase (JAK)
inhibitor INCB039110 (itacitinib). Presented at
22nd Congress European Hematology Association, 25
June 2017, Madrid, Spain, Abstract S794.
69. Carpenter PA, Flowers MED and Pavletic
SZ. Chronic graft-versus-host disease - clinical
manifestations and therapy. In: Stephen Forman
J, Negrin RS, Antin JH, et al. (eds) Thomas’
hematopoietic cell transplantation. Chichester, UK:
John Wiley & Sons, Ltd., 2016, pp. 1020–1039.
70. Lee SJ. Classification systems for chronic graftversus-host disease. Blood 2017; 129: 30–37.

journals.sagepub.com/home/tah

71. Zeiser R, Burchert A, Lengerke C, et al.
Ruxolitinib in corticosteroid-refractory graftversus-host disease after allogeneic stem cell
transplantation: a multicenter survey. Leukemia
2015; 29: 2062–2068.
72. Flynn R, Paz K, Du J, et al. Targeted Rhoassociated kinase 2 inhibition suppresses
murine and human chronic GVHD through a
Stat3-dependent mechanism. Blood 2016; 127:
2144–2154.
73. Chen W, Nyuydzefe MS, Weiss JM, et al.
ROCK2, but not ROCK1 interacts with
phosphorylated STAT3 and co-occupies TH17/
TFH gene promoters in TH17-activated human
T cells. Sci Rep 2018; 8: 2–11.
74. Jaglowski SM and Blazar BR. How ibrutinib,
a B-cell malignancy drug, became an FDAapproved second-line therapy for steroid-resistant
chronic GVHD. Blood Adv 2018; 2: 2012–2019.
75. Jagasia M, Ali H, Schroeder MA, et al.
Ruxolitinib in combination with corticosteroids
for the treatment of steroid-refractory acute
graft-vs-host disease: results from the phase 2
REACH1 trial. Biol Blood Marrow Transplant
2019; 25: S52.
76. Spoerl S, Mathew NR, Bscheider M, et al.
Activity of therapeutic JAK 1/2 blockade in
graft-versus-host disease. Blood 2014; 123:
3832–3842.
77. Harigai M. Growing evidence of the safety of JAK
inhibitors in patients with rheumatoid arthritis.
Rheumatol (Oxford) 2019; 58: i34–i42.
78. Harrison CN, Vannucchi AM, Kiladjian JJ, et al.
Long-term findings from COMFORT-II, a phase
3 study of ruxolitinib vs best available therapy for
myelofibrosis. Leukemia 2016; 30: 1701–1707.
79. Blechman AB, Cabell CE, Weinberger CH, et al.
Aggressive skin cancers occurring in patients
treated with the Janus Kinase inhibitor ruxolitinib.
J Drugs Dermatology 2017; 16: 508–511.
80. Lussana F, Cattaneo M, Rambaldi A, et al.
Ruxolitinib-associated infections: a systematic
review and meta-analysis. Am J Hematol 2018;
93: 339–347.
81. Zorn E, Nelson EA, Mohseni M, et al. IL-2
regulates FOXP3 expression in human
CD4+CD25+ regulatory T cells through a STATdependent mechanism and induces the expansion
of these cells in vivo. Blood 2006; 108: 1571–1579.
82. Yao Z, Kanno Y, Kerenyi M, et al.
Nonredundant roles for Stat5a/b in directly
regulating Foxp3. Blood 2007; 109: 4368–4375.

Visit SAGE journals online
journals.sagepub.com/
home/tah

SAGE journals

13

